KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma. [electronic resource]
Producer: 20170724Description: 325-33 p. digitalISSN:- 1365-2133
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal -- pharmacology
- Antineoplastic Agents -- pharmacology
- Cell Line, Tumor
- Female
- Humans
- Ki-1 Antigen -- metabolism
- Killer Cells, Natural -- physiology
- Leukocytes, Mononuclear -- metabolism
- Lymphoma, Large-Cell, Anaplastic -- drug therapy
- Male
- Middle Aged
- Receptors, KIR2DL2 -- antagonists & inhibitors
- Skin -- metabolism
- Skin Neoplasms -- drug therapy
- Tumor Cells, Cultured
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.